Anterogen.Co.Ltd (KQ:065660) — Market Cap & Net Worth
Market Cap & Net Worth: Anterogen.Co.Ltd (065660)
Anterogen.Co.Ltd (KQ:065660) has a market capitalization of $136.64 Million (₩201.62 Billion) as of June 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #18081 globally and #800 in its home market, demonstrating a 3.68% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Anterogen.Co.Ltd's stock price ₩25350.00 by its total outstanding shares 7953630 (7.95 Million). Review total liabilities of Anterogen.Co.Ltd to assess the company's total debt and financial obligations.
Anterogen.Co.Ltd Market Cap History: 2016 to 2026
Anterogen.Co.Ltd's market capitalization history from 2016 to 2026. Data shows change from $127.74 Million to $136.64 Million (-4.10% CAGR).
Index Memberships
Anterogen.Co.Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$270.08 Billion | 0.05% | #313 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$270.08 Billion | 0.05% | #313 of 1384 |
Weight: Anterogen.Co.Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Anterogen.Co.Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Anterogen.Co.Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Anterogen.Co.Ltd's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $127.74 Million | $4.90 Billion | $371.66 Million | 0.03x | 0.34x |
| 2017 | $247.94 Million | $5.36 Billion | $446.74 Million | 0.05x | 0.56x |
| 2018 | $381.08 Million | $3.61 Billion | -$961.76 Million | 0.11x | N/A |
| 2019 | $231.23 Million | $4.15 Billion | -$4.05 Billion | 0.06x | N/A |
| 2020 | $335.80 Million | $4.15 Billion | -$4.38 Billion | 0.08x | N/A |
| 2021 | $346.58 Million | $8.12 Billion | -$553.98 Million | 0.04x | N/A |
| 2022 | $79.23 Million | $6.59 Billion | -$6.84 Billion | 0.01x | N/A |
| 2023 | $92.12 Million | $6.50 Billion | -$2.84 Billion | 0.01x | N/A |
| 2024 | $101.82 Million | $6.93 Billion | -$2.29 Billion | 0.01x | N/A |
Competitor Companies of 065660 by Market Capitalization
Companies near Anterogen.Co.Ltd in the global market cap rankings as of June 19, 2026.
Key companies related to Anterogen.Co.Ltd by market ranking:
- Sam Chun Dang Pharm. Co. Ltd (KQ:000250): Ranked #4311 globally with a market cap of $3.82 Billion USD ( ₩5.63 Trillion KRW).
- ST Pharm Co.Ltd (KQ:237690): Ranked #7107 globally with a market cap of $1.61 Billion USD ( ₩2.37 Trillion KRW).
- NatureCell Co.Ltd (KQ:007390): Ranked #8654 globally with a market cap of $1.10 Billion USD ( ₩1.63 Trillion KRW).
- Oscotec Inc (KQ:039200): Ranked #10333 globally with a market cap of $755.10 Million USD ( ₩1.11 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #4311 | Sam Chun Dang Pharm. Co. Ltd | KQ:000250 | $3.82 Billion | ₩263000.00 |
| #7107 | ST Pharm Co.Ltd | KQ:237690 | $1.61 Billion | ₩127000.00 |
| #8654 | NatureCell Co.Ltd | KQ:007390 | $1.10 Billion | ₩30650.00 |
| #10333 | Oscotec Inc | KQ:039200 | $755.10 Million | ₩39650.00 |
Anterogen.Co.Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, Anterogen.Co.Ltd's market cap moved from $127.74 Million to $ 136.64 Million, with a yearly change of -4.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩136.64 Million | -45.89% |
| 2025 | ₩252.52 Million | +148.01% |
| 2024 | ₩101.82 Million | +10.53% |
| 2023 | ₩92.12 Million | +16.26% |
| 2022 | ₩79.23 Million | -77.14% |
| 2021 | ₩346.58 Million | +3.21% |
| 2020 | ₩335.80 Million | +45.22% |
| 2019 | ₩231.23 Million | -39.32% |
| 2018 | ₩381.08 Million | +53.70% |
| 2017 | ₩247.94 Million | +94.09% |
| 2016 | ₩127.74 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Anterogen.Co.Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $136.64 Million USD |
| MoneyControl | $136.64 Million USD |
| MarketWatch | $136.64 Million USD |
| marketcap.company | $136.64 Million USD |
| Reuters | $136.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Anterogen.Co.Ltd
Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of stem cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn's fistula; Queencell, a stromal vascular fraction used for the regen… Read more